RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

This study tests a single dose of an experimental RSV vaccine in Chinese adults aged 18 to 59 who have health conditions that raise their risk for severe RSV disease. Researchers will compare their immune response to that of older adults (60+) from a previous study. The trial als…

This study looks at how well an RSV vaccine works and how safe it is in adults who have had a lung or kidney transplant. About 184 participants will receive the vaccine to see if their immune response lasts and if a booster dose is safe. The goal is to help protect transplant rec…

This study looks at the best timing for a booster shot of the RSV vaccine in adults aged 60 and older. It will follow over 10,000 participants for up to 5 years to see how long protection lasts and whether a second dose is needed. The goal is to help prevent serious RSV infection…

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses of the vaccine at dif…

This phase 3 trial is testing a non-live, adjuvanted RSV vaccine (Arexvy) in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants…

This early-stage trial is testing a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune respo…

This study will check how well two RSV prevention methods work in real life: a vaccine given to pregnant women and an antibody shot given to newborns. Researchers will follow about 1,100 infants under 6 months old who are hospitalized with severe respiratory infections in Bogotá,…